of the Executive Committee and Division Head, Sandoz Kevin Buehler - Member of the Executive Committee, Division Head, Alcon Andrin Oswald - Division Head, Novartis Vaccines and Diagnostics Brian McNamara - Division Head, Novartis OTC George Gunn
Joining me on the Novartis end are Jon Symonds, CFO; David Epstein, Head of Pharma Division; Kevin Buehler, Head of the Alcon business; Jeff George, Head of Sandoz unit; Andrin Oswald, Head of Vaccines and Diagnostics; George Gunn, Head of
interesting recent news concerning NVS is that eye care company Alcon (a subsidiary of NVS) has announced that the US Food and ..... hypertension. Regarding the development, Robert Warner of Alcon commented as follows: The introduction of Simbrinza further
ZURICH, March 18 (Reuters) - Novartis said its Alcon unit got green light from the European Commission for Jetrea, a drug to treat an eye condition that can cause irreversible vision loss.
next several years.The addition of Alcon brings strong exposure to the second-fastest-growing ..... additional debt needed to fund the Alcon acquisition, we expect Novartis will ..... Further, the much larger acquisition of Alcon in the rapidly growing eye-care market
enormous variety of brands. You can see a full list here . Alcon is a global company specializing in eye care. Novartis bought it from Nestlé in 2010. In 2012, Alcon contributed just over $10 billion in net sales. Sandoz
by a healthy growth in the wet-AMD, Dry Eye Syndrome (DES) and Diabetic Macular Edema (DME). The drug ophthalmology market is dominated by six large companies - Pfizer Inc. ( PFE ), Allergan Inc. ( AGN ), Alcon Complete Story »
Jan 23 (Reuters) - The U.S. Attorney for the Northern District of Texas is investigating the export of products made by Novartis AG's Alcon eye care unit to Iran and other countries subject to trade sanctions, the company said on Wednesday.
Jan 23 (Reuters) - Novartis AG : * Says Alcon Laboratories was notified in 2012 of Northern District of Texas probe - SEC filing * Says probe related to exporting products to Iran - SEC filing * Says Alcon received grand jury subpoena for documents back to 2005 - SEC
CEO Samir Shah - Global Head IR Jon Symonds - our CFO David Epstein - Head of the Pharma division Kevin Buehler - Head of Alcon Jeff George - Head of Sandoz division Andrin Oswald - Head of Vaccines & Diagnostics Brian Mcnamara - Head of OTC Analysts